Back to today’s briefing

Story perspectives

FDA Warns: Glatiramer Acetate Linked to Anaphylaxis Risks

1/23/2025

32 4

Summary

Story summary

The FDA has issued a serious boxed warning for glatiramer acetate, a drug used to treat multiple sclerosis, highlighting the risk of life-threatening anaphylaxis. Between 1996 and 2024, there were 82 reported cases, resulting in 51 hospitalizations and 6 fatalities. Patients are urged to seek urgent medical attention if symptoms develop, which can occur at any time, often within an hour of injection.

1 of 1

Story summary

The FDA has issued a serious boxed warning for glatiramer acetate, a drug used to treat multiple sclerosis, highlighting the risk of life-threatening anaphylaxis. Between 1996 and 2024, there were 82 reported cases, resulting in 51 hospitalizations and 6 fatalities. Patients are urged to seek urgent medical attention if symptoms develop, which can occur at any time, often within an hour of injection.